Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling

References

• Atkinson MA, von Herrath M, Powers AC, Clare-Salzler M. Current concepts on the pathogenesis of type 1 diabetes—considerations for attempts to prevent and reverse the disease. Diabetes Care. 2015;38(6):979–988. doi:10.2337/dc15-0144
   PubMed Web of Science ®Google Scholar
• Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. 2015;6(3):456. doi:10.4239/wjd.v6.i3.456
   PubMed Web of Science ®Google Scholar
• Tallapragada DSP, Bhaskar S, Chandak GR. New insights from monogenic diabetes for “common” type 2 diabetes. Front Genet. 2015;6:251. doi:10.3389/fgene.2015.00251
   Web of Science ®Google Scholar
• James DE, Stöckli J, Birnbaum MJ. The aetiology and molecular landscape of insulin resistance. Nat Rev Mol Cell Biol. 2021;22(11):751–771. doi:10.1038/s41580-021-00390-6
   PubMed Web of Science ®Google Scholar
• Pipatpolkai T, Usher S, Stansfeld PJ, Ashcroft FM. New insights into K ATP channel gene mutations and neonatal diabetes mellitus. Nat Rev Endocrinol. 2020;16(7):378–393. doi:10.1038/s41574-020-0351-y
   Web of Science ®Google Scholar
• Lin Y-W, Akrouh A, Hsu Y, Hughes N, Nichols CG, De León DD. Compound heterozygous mutations in the SUR1 (ABCC 8) subunit of pancreatic KATP channels cause neonatal diabetes by perturbing the coupling between Kir6. 2 and SUR1 subunits. Channels. 2012;6(2):133–138. doi:10.4161/chan.19980
   PubMed Web of Science ®Google Scholar
• Avior Y, Sagi I, Benvenisty N. Pluripotent stem cells in disease modelling and drug discovery. Nat Rev Mol Cell Biol. 2016;17(3):170–182. doi:10.1038/nrm.2015.27
   PubMed Web of Science ®Google Scholar
• Merkle FT, Eggan K. Modeling human disease with pluripotent stem cells: from genome association to function. Cell Stem Cell. 2013;12(6):656–668. doi:10.1016/j.stem.2013.05.016
   PubMed Web of Science ®Google Scholar
• Abdelalim EM, Bonnefond A, Bennaceur-Griscelli A, Froguel P. Pluripotent stem cells as a potential tool for disease modelling and cell therapy in diabetes. Stem Cell Rev Rep. 2014;10(3):327–337. doi:10.1007/s12015-014-9503-6
   Web of Science ®Google Scholar
• Al‐Khawaga S, Memon B, Butler AE, Taheri S, Abou‐Samra AB, Abdelalim EM. Pathways governing development of stem cell‐derived pancreatic β cells: lessons from embryogenesis. Biol Rev. 2018;93(1):364–389. doi:10.1111/brv.12349
   Web of Science ®Google Scholar
• Lim WF, Inoue-Yokoo T, Tan KS, Lai MI, Sugiyama D. Hematopoietic cell differentiation from embryonic and induced pluripotent stem cells. Stem Cell Res Ther. 2013;4(3):1–11. doi:10.1186/scrt222
   Web of Science ®Google Scholar
• Sauer V, Roy-Chowdhury N, Guha C, Roy-Chowdhury J. Induced pluripotent stem cells as a source of hepatocytes. Curr Pathobiol Rep. 2014;2(1):11–20. doi:10.1007/s40139-013-0039-2
   PubMedGoogle Scholar
• Bassett AR. Editing the genome of hiPSC with CRISPR/Cas9: disease models. Mamm Genome. 2017;28(7):348–364. doi:10.1007/s00335-017-9684-9
   Web of Science ®Google Scholar
• Cong L, Zhang F. Genome engineering using CRISPR-Cas9 system. In: Chromosomal Mutagenesis. Springer; 2015:197–217.
   Google Scholar
• Abdelalim EM. Modeling different types of diabetes using human pluripotent stem cells. Cell Mol Life Sci. 2021;78(6):2459–2483. doi:10.1007/s00018-020-03710-9
   Web of Science ®Google Scholar
• Misra S, Owen KR. Genetics of monogenic diabetes: present clinical challenges. Curr Diab Rep. 2018;18(12):1–11. doi:10.1007/s11892-018-1111-4
   Web of Science ®Google Scholar
• Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic β-cell diabetes. Nat Clin Pract Endocrinol Metab. 2008;4(4):200–213.
   PubMedGoogle Scholar
• Anık A, Çatlı G, Abacı A, Böber E. Maturity-onset diabetes of the young (MODY): an update. J Pediatr Endocrinol Metab. 2015;28(3–4):251–263. doi:10.1515/jpem-2014-0384
   PubMed Web of Science ®Google Scholar
• Sanyoura M, Philipson LH, Naylor R. Monogenic diabetes in children and adolescents: recognition and treatment options. Curr Diab Rep. 2018;18(8):1–13. doi:10.1007/s11892-018-1024-2
   Web of Science ®Google Scholar
• Vaxillaire M, Bonnefond A, Froguel P. The lessons of early-onset monogenic diabetes for the understanding of diabetes pathogenesis. Best Pract Res Clin Endocrinol Metab. 2012;26(2):171–187. doi:10.1016/j.beem.2011.12.001
   Web of Science ®Google Scholar
• Hattersley AT, Patel KA. Precision diabetes: learning from monogenic diabetes. Diabetologia. 2017;60(5):769–777. doi:10.1007/s00125-017-4226-2
   PubMed Web of Science ®Google Scholar
• Inoue I, Nakaoka H. Genetics of diabetes: are they thrifty genotype? In: Evolution of the Human Genome I. Springer; 2017:265–272.
   Google Scholar
• Lim SH, Kim JH, Han KH, et al. Genotype and phenotype analyses in pediatric patients with HNF1B mutations. J Clin Med. 2020;9(7):2320. doi:10.3390/jcm9072320
   Web of Science ®Google Scholar
• Valkovicova T, Skopkova M, Stanik J, Gasperikova D. Novel insights into genetics and clinics of the HNF1A-MODY. Endocr Regul. 2019;53(2):110–134. doi:10.2478/enr-2019-0013
   PubMedGoogle Scholar
• Nkonge KM, Nkonge DK, Nkonge TN. The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY). Clin Diabetes Endocrinol. 2020;6(1):1–10. doi:10.1186/s40842-020-00112-5
   Google Scholar
• Laimon W, El-Ziny M, El-Hawary A, et al. Genetic and clinical heterogeneity of permanent neonatal diabetes mellitus: a single tertiary centre experience. Acta Diabetol. 2021;58(12):1689–1700. doi:10.1007/s00592-021-01788-6
   Web of Science ®Google Scholar
• Lemelman MB, Letourneau L, Greeley SAW. Neonatal diabetes mellitus: an update on diagnosis and management. Clin Perinatol. 2018;45(1):41–59. doi:10.1016/j.clp.2017.10.006
   PubMed Web of Science ®Google Scholar
• Demirbilek H, Hatipoglu N, Gul U, et al. Permanent neonatal diabetes mellitus and neurological abnormalities due to a novel homozygous missense mutation in NEUROD1. Pediatr Diabetes. 2018;19(5):898–904. doi:10.1111/pedi.12669
   PubMed Web of Science ®Google Scholar
• Gopi S, Gowri P, Panda JK, et al. Insulin gene mutations linked to permanent neonatal diabetes mellitus in Indian population. J Diabetes Complications. 2021;35(12):108022. doi:10.1016/j.jdiacomp.2021.108022
   Web of Science ®Google Scholar
• Touati A, Errea-Dorronsoro J, Nouri S, et al. Transient neonatal diabetes mellitus and hypomethylation at additional imprinted loci: novel ZFP57 mutation and review on the literature. Acta Diabetol. 2019;56(3):301–307. doi:10.1007/s00592-018-1239-3
   Web of Science ®Google Scholar
• De Franco E, Flanagan SE, Houghton JA, et al. The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study. Lancet. 2015;386(9997):957–963. doi:10.1016/S0140-6736(15)60098-8
   PubMed Web of Science ®Google Scholar
• Greeley SAW, Tucker SE, Naylor RN, Bell GI, Philipson LH. Neonatal diabetes mellitus: a model for personalized medicine. Trends Endocrinol Metabol. 2010;21(8):464–472. doi:10.1016/j.tem.2010.03.004
   Web of Science ®Google Scholar
• Busiah K, Drunat S, Vaivre-Douret L, et al. Neuropsychological dysfunction and developmental defects associated with genetic changes in infants with neonatal diabetes mellitus: a prospective cohort study. Lancet Diabetes Endocrinol. 2013;1(3):199–207. doi:10.1016/S2213-8587(13)70059-7
   Web of Science ®Google Scholar
• Kamiya M, Judson H, Okazaki Y, et al. The cell cycle control gene ZAC/PLAGL1 is imprinted—a strong candidate gene for transient neonatal diabetes. Hum Mol Genet. 2000;9(3):453–460. doi:10.1093/hmg/9.3.453
   PubMed Web of Science ®Google Scholar
• Temple IK, Shield JP. 6q24 transient neonatal diabetes. Rev Endocr Metab Disord. 2010;11(3):199–204. doi:10.1007/s11154-010-9150-4
   PubMed Web of Science ®Google Scholar
• Støy J, Steiner DF, Park S-Y, Ye H, Philipson LH, Bell GI. Clinical and molecular genetics of neonatal diabetes due to mutations in the insulin gene. Rev Endocr Metab Disord. 2010;11(3):205–215.
   PubMed Web of Science ®Google Scholar
• Park S-Y, Ye H, Steiner DF, Bell GI. Mutant proinsulin proteins associated with neonatal diabetes are retained in the endoplasmic reticulum and not efficiently secreted. Biochem Biophys Res Commun. 2010;391(3):1449–1454. doi:10.1016/j.bbrc.2009.12.090
   PubMed Web of Science ®Google Scholar
• Singh VK, Saini A, Kalsan M, Kumar N, Chandra R. Describing the stem cell potency: the various methods of functional assessment and in silico diagnostics. Front Cell Develop Biol. 2016;4:134. doi:10.3389/fcell.2016.00134
   Web of Science ®Google Scholar
• Lin Y, Linask KL, Mallon B, et al. Heparin promotes cardiac differentiation of human pluripotent stem cells in chemically defined albumin‐free medium, enabling consistent manufacture of cardiomyocytes. Stem Cells Transl Med. 2017;6(2):527–538. doi:10.5966/sctm.2015-0428
   Web of Science ®Google Scholar
• Takahashi K, Tanabe MO, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;2007(11):1–12.
   Google Scholar
• Ilic D, Ogilvie C. Concise review: human embryonic stem cells—what have we done? What are we doing? Where are we going? Stem Cells. 2017;35(1):17–25. doi:10.1002/stem.2450
   Web of Science ®Google Scholar
• King NM, Perrin J. Ethical issues in stem cell research and therapy. Stem Cell Res Ther. 2014;5(4):1–6. doi:10.1186/scrt474
   Web of Science ®Google Scholar
• Jaiswal MK. Therapeutic opportunities and challenges of induced pluripotent stem cells-derived motor neurons for treatment of amyotrophic lateral sclerosis and motor neuron disease. Neural Regen Res. 2017;12(5):723. doi:10.4103/1673-5374.206635
   Web of Science ®Google Scholar
• McKinney CE. Using induced pluripotent stem cells derived neurons to model brain diseases. Neural Regen Res. 2017;12(7):1062. doi:10.4103/1673-5374.211180
   Web of Science ®Google Scholar
• Memon B, Abdelalim EM. Stem cell therapy for diabetes: beta cells versus pancreatic progenitors. Cells. 2020;9(2):283. doi:10.3390/cells9020283
   Web of Science ®Google Scholar
• Memon B, Karam M, Al-Khawaga S, Abdelalim EM. Enhanced differentiation of human pluripotent stem cells into pancreatic progenitors co-expressing PDX1 and NKX6. Stem Cell Res Ther. 2018;9(1):1–15.
   Google Scholar
• Nostro MC, Sarangi F, Yang C, et al. Efficient generation of NKX6-1+ pancreatic progenitors from multiple human pluripotent stem cell lines. Stem Cell Rep. 2015;4(4):591–604. doi:10.1016/j.stemcr.2015.02.017
   Web of Science ®Google Scholar
• Boroviak T, Loos R, Bertone P, Smith A, Nichols J. The ability of inner-cell-mass cells to self-renew as embryonic stem cells is acquired following epiblast specification. Nat Cell Biol. 2014;16(6):513–525. doi:10.1038/ncb2965
   Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. cell. 2006;126(4):663–676. doi:10.1016/j.cell.2006.07.024
   PubMed Web of Science ®Google Scholar
• Burgos JI, Vallier L, Rodríguez-Seguí SA. Monogenic diabetes modeling: in vitro pancreatic differentiation from human pluripotent stem cells gains momentum. Front Endocrinol. 2021;12:692596.
   Web of Science ®Google Scholar
• Karagiannis P, Takahashi K, Saito M, et al. Induced pluripotent stem cells and their use in human models of disease and development. Physiol Rev. 2019;99(1):79–114. doi:10.1152/physrev.00039.2017
   PubMed Web of Science ®Google Scholar
• Teo AKK, Wagers AJ, Kulkarni RN. New opportunities: harnessing induced pluripotency for discovery in diabetes and metabolism. Cell Metab. 2013;18(6):775–791. doi:10.1016/j.cmet.2013.08.010
   Web of Science ®Google Scholar
• Rezania A, Bruin JE, Arora P, et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol. 2014;32(11):1121–1133. doi:10.1038/nbt.3033
   PubMed Web of Science ®Google Scholar
• Teo AK, Windmueller R, Johansson BB, et al. Derivation of human induced pluripotent stem cells from patients with maturity onset diabetes of the young*[S]. J Biol Chem. 2013;288(8):5353–5356. doi:10.1074/jbc.C112.428979
   Web of Science ®Google Scholar
• Shang L, Hua H, Foo K, et al. β-cell dysfunction due to increased ER stress in a stem cell model of Wolfram syndrome. Diabetes. 2014;63(3):923–933. doi:10.2337/db13-0717
   Web of Science ®Google Scholar
• Urano F. Wolfram syndrome: diagnosis, management, and treatment. Curr Diab Rep. 2016;16(1):6. doi:10.1007/s11892-015-0702-6
   PubMed Web of Science ®Google Scholar
• Ng NHJ, Jasmen JB, Lim CS, et al. HNF4A haploinsufficiency in MODY1 abrogates liver and pancreas differentiation from patient-derived induced pluripotent stem cells. Iscience. 2019;16:192–205. doi:10.1016/j.isci.2019.05.032
   PubMed Web of Science ®Google Scholar
• Boj SF, Petrov D, Ferrer J. Epistasis of transcriptomes reveals synergism between transcriptional activators Hnf1α and Hnf4α. PLoS Genet. 2010;6(5):e1000970. doi:10.1371/journal.pgen.1000970
   Web of Science ®Google Scholar
• Balboa D, Saarimäki-Vire J, Borshagovski D, et al. Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes. Elife. 2018;7:e38519. doi:10.7554/eLife.38519
   Web of Science ®Google Scholar
• Ma S, Viola R, Sui L, Cherubini V, Barbetti F, Egli D. Beta cell replacement after gene editing of a neonatal diabetes-causing mutation at the insulin locus. Stem Cell Rep. 2018;11(6):1407–1415. doi:10.1016/j.stemcr.2018.11.006
   PubMed Web of Science ®Google Scholar
• Khan SH. Genome-editing technologies: concept, pros, and cons of various genome-editing techniques and bioethical concerns for clinical application. Mol Ther Nucleic Acids. 2019;16:326–334. doi:10.1016/j.omtn.2019.02.027
   PubMedGoogle Scholar
• Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010;11(9):636–646. doi:10.1038/nrg2842
   PubMed Web of Science ®Google Scholar
• Carroll D. Genome engineering with zinc-finger nucleases. Genetics. 2011;188(4):773–782. doi:10.1534/genetics.111.131433
   PubMed Web of Science ®Google Scholar
• Paschon DE, Lussier S, Wangzor T, et al. Diversifying the structure of zinc finger nucleases for high-precision genome editing. Nat Commun. 2019;10(1):1–12. doi:10.1038/s41467-019-08867-x
   Web of Science ®Google Scholar
• Jabalameli HR, Zahednasab H, Karimi-Moghaddam A, Jabalameli MR. Zinc finger nuclease technology: advances and obstacles in modelling and treating genetic disorders. Gene. 2015;558(1):1–5. doi:10.1016/j.gene.2014.12.044
   Web of Science ®Google Scholar
• Christian M, Cermak T, Doyle EL, et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics. 2010;186(2):757–761. doi:10.1534/genetics.110.120717
   PubMed Web of Science ®Google Scholar
• Miller JC, Tan S, Qiao G, et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol. 2011;29(2):143–148. doi:10.1038/nbt.1755
   PubMed Web of Science ®Google Scholar
• Chandrasegaran S, Carroll D. Origins of programmable nucleases for genome engineering. J Mol Biol. 2016;428(5):963–989. doi:10.1016/j.jmb.2015.10.014
   PubMed Web of Science ®Google Scholar
• Moscou MJ, Bogdanove AJ. A simple cipher governs DNA recognition by TAL effectors. Science. 2009;326(5959):1501. doi:10.1126/science.1178817
   PubMed Web of Science ®Google Scholar
• Cong L, Zhou R, Kuo Y-C, Cunniff M, Zhang F. Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains. Nat Commun. 2012;3(1):1–6. doi:10.1038/ncomms1962
   Web of Science ®Google Scholar
• Streubel J, Blücher C, Landgraf A, Boch J. TAL effector RVD specificities and efficiencies. Nat Biotechnol. 2012;30(7):593–595. doi:10.1038/nbt.2304
   Web of Science ®Google Scholar
• Guilinger JP, Pattanayak V, Reyon D, et al. Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nat Methods. 2014;11(4):429–435. doi:10.1038/nmeth.2845
   Web of Science ®Google Scholar
• Juillerat A, Pessereau C, Dubois G, et al. Optimized tuning of TALEN specificity using non-conventional RVDs. Sci Rep. 2015;5(1):1–7. doi:10.1038/srep08150
   Web of Science ®Google Scholar
• Yang J, Zhang Y, Yuan P, et al. Complete decoding of TAL effectors for DNA recognition. Cell Res. 2014;24(5):628–631. doi:10.1038/cr.2014.19
   Web of Science ®Google Scholar
• Gaj T, Sirk SJ, Shui S-l S-L, Liu J. Genome-editing technologies: principles and applications. Cold Spring Harb Perspect Biol. 2016;8(12):a023754. doi:10.1101/cshperspect.a023754
   Web of Science ®Google Scholar
• Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. science. 2012;337(6096):816–821. doi:10.1126/science.1225829
   PubMed Web of Science ®Google Scholar
• Makarova KS, Haft DH, Barrangou R, et al. Evolution and classification of the CRISPR–Cas systems. Nat Rev Microbiol. 2011;9(6):467–477. doi:10.1038/nrmicro2577
   PubMed Web of Science ®Google Scholar
• Wright AV, Nuñez JK, Doudna JA. Biology and applications of CRISPR systems: harnessing nature’s toolbox for genome engineering. Cell. 2016;164(1–2):29–44. doi:10.1016/j.cell.2015.12.035
   PubMed Web of Science ®Google Scholar
• Wiedenheft B, Sternberg SH, Doudna JA. RNA-guided genetic silencing systems in bacteria and archaea. Nature. 2012;482(7385):331–338. doi:10.1038/nature10886
   PubMed Web of Science ®Google Scholar
• Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339(6121):823–826. doi:10.1126/science.1232033
   PubMed Web of Science ®Google Scholar
• Ming S, Tian-Rui X, Ce-Shi C. The big bang of genome editing technology: development and application of the CRISPR/Cas9 system in disease animal models. Zoo Res. 2016;37(4):191. doi:10.13918/j.issn.2095-8137.2016.4.191
   Web of Science ®Google Scholar
• Ceasar SA, Rajan V, Prykhozhij SV, Berman JN, Ignacimuthu S. Insert, remove or replace: a highly advanced genome editing system using CRISPR/Cas9. Biochim Biophys Acta Mol Cell Res. 2016;1863(9):2333–2344. doi:10.1016/j.bbamcr.2016.06.009
   PubMed Web of Science ®Google Scholar
• Jiang F, Doudna JA. CRISPR–Cas9 structures and mechanisms. Annu Rev Biophys. 2017;46(1):505–529. doi:10.1146/annurev-biophys-062215-010822
   PubMed Web of Science ®Google Scholar
• Mei Y, Wang Y, Chen H, Sun ZS, Ju X-D. Recent progress in CRISPR/Cas9 technology. J Genet Genomics. 2016;43(2):63–75. doi:10.1016/j.jgg.2016.01.001
   Web of Science ®Google Scholar
• Deng L, Luo M, Velikovsky A, Mariuzza RA. Structural insights into the evolution of the adaptive immune system. Annu Rev Biophys. 2013;42(1):191–215. doi:10.1146/annurev-biophys-083012-130422
   Web of Science ®Google Scholar
• Tiyaboonchai A, Cardenas-Diaz FL, Ying L, et al. GATA6 plays an important role in the induction of human definitive endoderm, development of the pancreas, and functionality of pancreatic β cells. Stem Cell Rep. 2017;8(3):589–604. doi:10.1016/j.stemcr.2016.12.026
   Web of Science ®Google Scholar
• Zeng H, Guo M, Zhou T, et al. An isogenic human ESC platform for functional evaluation of genome-wide-association-study-identified diabetes genes and drug discovery. Cell Stem Cell. 2016;19(3):326–340. doi:10.1016/j.stem.2016.07.002
   Web of Science ®Google Scholar
• Shi Z-D, Lee K, Yang D, et al. Genome editing in hPSCs reveals GATA6 haploinsufficiency and a genetic interaction with GATA4 in human pancreatic development. Cell Stem Cell. 2017;20(5):675–88. e6. doi:10.1016/j.stem.2017.01.001
   Web of Science ®Google Scholar
• Zhu Z, González F, Huangfu D. The iCRISPR platform for rapid genome editing in human pluripotent stem cells. Methods Enzymol. 2014;546:215–250.
   Web of Science ®Google Scholar
• Nostro MC, Keller G. Generation of beta cells from human pluripotent stem cells: potential for regenerative medicine. In: Seminars in Cell & Developmental Biology. Elsevier; 2012.
   Google Scholar
• Pagliuca FW, Millman JR, Gürtler M, et al. Generation of functional human pancreatic β cells in vitro. Cell. 2014;159(2):428–439. doi:10.1016/j.cell.2014.09.040
   PubMed Web of Science ®Google Scholar
• Balboa D, Saarimäki‐Vire J, Otonkoski T. Concise review: human pluripotent stem cells for the modeling of pancreatic β‐cell pathology. Stem Cells. 2019;37(1):33–41. doi:10.1002/stem.2913
   PubMed Web of Science ®Google Scholar
• Gupta N, Susa K, Yoda Y, Bonventre JV, Valerius MT, Morizane R. CRISPR/Cas9‐based targeted genome editing for the development of monogenic diseases models with human pluripotent stem cells. Curr Protoc Stem Cell Biol. 2018;45(1):e50. doi:10.1002/cpsc.50
   Google Scholar
• Zhu Z, Li QV, Lee K, et al. Genome editing of lineage determinants in human pluripotent stem cells reveals mechanisms of pancreatic development and diabetes. Cell Stem Cell. 2016;18(6):755–768. doi:10.1016/j.stem.2016.03.015
   Web of Science ®Google Scholar
• Brissova M, Blaha M, Spear C, et al. Reduced PDX-1 expression impairs islet response to insulin resistance and worsens glucose homeostasis. Am J Physiol Endocrinol Metab. 2005;288(4):E707–E14. doi:10.1152/ajpendo.00252.2004
   PubMed Web of Science ®Google Scholar
• Johnson JD, Ahmed NT, Luciani DS, et al. Increased islet apoptosis in Pdx1+/–mice. J Clin Invest. 2003;111(8):1147–1160. doi:10.1172/JCI200316537
   PubMed Web of Science ®Google Scholar
• Cardenas-Diaz FL, Osorio-Quintero C, Diaz-Miranda MA, et al. Modeling monogenic diabetes using human ESCs reveals developmental and metabolic deficiencies caused by mutations in HNF1A. Cell Stem Cell. 2019;25(2):273–89. e5. doi:10.1016/j.stem.2019.07.007
   Web of Science ®Google Scholar
• Chia CY, Madrigal P, Denil SL, et al. GATA6 cooperates with EOMES/SMAD2/3 to deploy the gene regulatory network governing human definitive endoderm and pancreas formation. Stem Cell Rep. 2019;12(1):57–70. doi:10.1016/j.stemcr.2018.12.003
   Web of Science ®Google Scholar
• Braverman-Gross C, Nudel N, Ronen D, Beer NL, McCarthy MI, Benvenisty N. Derivation and molecular characterization of pancreatic differentiated MODY1-iPSCs. Stem Cell Res. 2018;31:16–26. doi:10.1016/j.scr.2018.06.013
   Web of Science ®Google Scholar
• Colclough K, Bellanne‐Chantelot C, Saint‐Martin C, Flanagan SE, Ellard S. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity‐onset diabetes of the young and hyperinsulinemic hypoglycemia. Hum Mutat. 2013;34(5):669–685. doi:10.1002/humu.22279
   PubMed Web of Science ®Google Scholar
• Pearson ER, Boj SF, Steele AM, et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med. 2007;4(4):e118. doi:10.1371/journal.pmed.0040118
   PubMed Web of Science ®Google Scholar
• Yamagata K, Oda N, Kaisaki PJ, et al. Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3). Nature. 1996;384(6608):455–458. doi:10.1038/384455a0
   PubMed Web of Science ®Google Scholar
• Aqel YWA, Ali G, Elsayed AK, Al-Khawaga S, Hussain K, Abdelalim EM. Generation of two human iPSC lines from patients with maturity-onset diabetes of the young type 2 (MODY2) and permanent neonatal diabetes due to mutations in the GCK gene. Stem Cell Res. 2020;48:101991. doi:10.1016/j.scr.2020.101991
   Web of Science ®Google Scholar
• Vionnet N, Stoffel M, Takeda J, et al. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature. 1992;356(6371):721–722. doi:10.1038/356721a0
   Web of Science ®Google Scholar
• Low BSJ, Lim CS, Ding SSL, et al. Decreased GLUT2 and glucose uptake contribute to insulin secretion defects in MODY3/HNF1A hiPSC-derived mutant β cells. Nat Commun. 2021;12(1):1–20. doi:10.1038/s41467-021-22843-4
   Web of Science ®Google Scholar
• Teo AKK, Lau HH, Valdez IA, et al. Early developmental perturbations in a human stem cell model of MODY5/HNF1B pancreatic hypoplasia. Stem Cell Rep. 2016;6(3):357–367. doi:10.1016/j.stemcr.2016.01.007
   PubMed Web of Science ®Google Scholar
• Horikawa Y, Iwasaki N, Hara M, et al. Mutation in hepatocyte nuclear factor–1β gene (TCF2) associated with MODY. Nat Genet. 1997;17(4):384–385. doi:10.1038/ng1297-384
   PubMed Web of Science ®Google Scholar
• Bouillet B, Crevisy E, Baillot-Rudoni S, et al. Whole-exome sequencing identifies the first French MODY 6 family with a new mutation in the NEUROD1 gene. Diabetes Metab. 2020;46(5):400–402. doi:10.1016/j.diabet.2020.03.001
   Web of Science ®Google Scholar
• Neve B, Fernandez-Zapico ME, Ashkenazi-Katalan V, et al. Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic beta cell function. Proc Nat Acad Sci. 2005;102(13):4807–4812. doi:10.1073/pnas.0409177102
   PubMed Web of Science ®Google Scholar
• Johansson BB, Torsvik J, Bjørkhaug L, et al. Diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl ester lipase gene-maturity onset diabetes of the young (CEL-MODY): a protein misfolding disease. J Biol Chem. 2011;286(40):34593–34605. doi:10.1074/jbc.M111.222679
   PubMed Web of Science ®Google Scholar
• de Medeiros Abreu G, CdAPD S, Tarantino RM, et al. Identification of the first PAX4-MODY family reported in Brazil. Diabetes Metab Syndr Obes. 2020;13:2623. doi:10.2147/DMSO.S256858
   Web of Science ®Google Scholar
• Plengvidhya N, Kooptiwut S, Songtawee N, et al. PAX4 mutations in Thais with maturity onset diabetes of the young. J Clin Endocrinol Metab. 2007;92(7):2821–2826. doi:10.1210/jc.2006-1927
   PubMed Web of Science ®Google Scholar
• Borowiec M, Liew CW, Thompson R, et al. Mutations at the BLK locus linked to maturity onset diabetes of the young and β-cell dysfunction. Proc Nat Acad Sci. 2009;106(34):14460–14465. doi:10.1073/pnas.0906474106
   Web of Science ®Google Scholar
• Lin L, Quan H, Chen K, Chen D, Lin D, Fang T. ABCC8-related maturity-onset diabetes of the young (MODY12): a report of a Chinese family. Front Endocrinol (Lausanne). 2020;11:645. doi:10.3389/fendo.2020.00645
   Web of Science ®Google Scholar
• Ovsyannikova AK, Rymar OD, Shakhtshneider EV, et al. ABCC8-related maturity-onset diabetes of the young (MODY12): clinical features and treatment perspective. Diabetes Ther. 2016;7(3):591–600. doi:10.1007/s13300-016-0192-9
   Web of Science ®Google Scholar
• Mlynarski W, Tarasov AI, Gach A, et al. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. Nat Clin Pract Neurol. 2007;3(11):640–645. doi:10.1038/ncpneuro0640
   PubMedGoogle Scholar
• Prudente S, Jungtrakoon P, Marucci A, et al. Loss-of-function mutations in APPL1 in familial diabetes mellitus. Am J Hum Genet. 2015;97(1):177–185. doi:10.1016/j.ajhg.2015.05.011
   PubMed Web of Science ®Google Scholar
• Støy J, Edghill EL, Flanagan SE, et al. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Nat Acad Sci. 2007;104(38):15040–15044. doi:10.1073/pnas.0707291104
   PubMed Web of Science ®Google Scholar
• Allen HL, Flanagan SE, Shaw-Smith C, et al. GATA6 haploinsufficiency causes pancreatic agenesis in humans. Nat Genet. 2012;44(1):20–22. doi:10.1038/ng.1035
   Web of Science ®Google Scholar
• Bonnefond A, Sand O, Guerin B, et al. GATA6 inactivating mutations are associated with heart defects and, inconsistently, with pancreatic agenesis and diabetes. Diabetologia. 2012;55(10):2845–2847. doi:10.1007/s00125-012-2645-7
   Web of Science ®Google Scholar
• Senée V, Vattem KM, Delépine M, et al. Wolcott-Rallison Syndrome: clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity. Diabetes. 2004;53(7):1876–1883. doi:10.2337/diabetes.53.7.1876
   PubMed Web of Science ®Google Scholar
• Gupta S, McGrath B, Cavener DR. PERK (EIF2AK3) regulates proinsulin trafficking and quality control in the secretory pathway. Diabetes. 2010;59(8):1937–1947. doi:10.2337/db09-1064
   PubMed Web of Science ®Google Scholar
• Osbak KK, Colclough K, Saint‐Martin C, et al. Update on mutations in glucokinase (GCK), which cause maturity‐onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat. 2009;30(11):1512–1526. doi:10.1002/humu.21110
   PubMed Web of Science ®Google Scholar
• Sellick GS, Barker KT, Stolte-Dijkstra I, et al. Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat Genet. 2004;36(12):1301–1305. doi:10.1038/ng1475
   PubMed Web of Science ®Google Scholar
• Weedon MN, Cebola I, Patch A-M, et al. Recessive mutations in a distal PTF1A enhancer cause isolated pancreatic agenesis. Nat Genet. 2014;46(1):61–64. doi:10.1038/ng.2826
   PubMed Web of Science ®Google Scholar
• Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27(1):20–21. doi:10.1038/83713
   PubMed Web of Science ®Google Scholar
• Senée V, Chelala C, Duchatelet S, et al. Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism. Nat Genet. 2006;38(6):682–687. doi:10.1038/ng1802
   PubMed Web of Science ®Google Scholar
• Nicolino M, Claiborn KC, Senée V, Boland A, Stoffers DA, Julier C. A novel hypomorphic PDX1 mutation responsible for permanent neonatal diabetes with subclinical exocrine deficiency. Diabetes. 2010;59(3):733–740. doi:10.2337/db09-1284
   PubMed Web of Science ®Google Scholar
• Sansbury F, Flanagan S, Houghton J, et al. SLC2A2 mutations can cause neonatal diabetes, suggesting GLUT2 may have a role in human insulin secretion. Diabetologia. 2012;55(9):2381–2385. doi:10.1007/s00125-012-2595-0
   PubMed Web of Science ®Google Scholar
• Labay V, Raz T, Baron D, et al. Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness. Nat Genet. 1999;22(3):300–304. doi:10.1038/10372
   PubMed Web of Science ®Google Scholar
• Rubio-Cabezas O, Jensen JN, Hodgson MI, et al. Permanent neonatal diabetes and enteric anendocrinosis associated with biallelic mutations in NEUROG3. Diabetes. 2011;60(4):1349–1353. doi:10.2337/db10-1008
   Web of Science ®Google Scholar
• Ketola I, Otonkoski T, Pulkkinen M-A, et al. Transcription factor GATA-6 is expressed in the endocrine and GATA-4 in the exocrine pancreas. Mol Cell Endocrinol. 2004;226(1–2):51–57. doi:10.1016/j.mce.2004.06.007
   Web of Science ®Google Scholar
• Naya FJ, Huang H-P, Qiu Y, et al. Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine differentiation in BETA2/neuroD-deficient mice. Genes Dev. 1997;11(18):2323–2334. doi:10.1101/gad.11.18.2323
   PubMed Web of Science ®Google Scholar
• Rubio-Cabezas O, Minton JA, Kantor I, Williams D, Ellard S, Hattersley AT. Homozygous mutations in NEUROD1 are responsible for a novel syndrome of permanent neonatal diabetes and neurological abnormalities. Diabetes. 2010;59(9):2326–2331. doi:10.2337/db10-0011
   PubMed Web of Science ®Google Scholar
• Pinney SE, Oliver-Krasinski J, Ernst L, et al. Neonatal diabetes and congenital malabsorptive diarrhea attributable to a novel mutation in the human neurogenin-3 gene coding sequence. J Clin Endocrinol Metab. 2011;96(7):1960–1965. doi:10.1210/jc.2011-0029
   Web of Science ®Google Scholar
• Flanagan SE, De Franco E, Allen HL, et al. Analysis of transcription factors key for mouse pancreatic development establishes NKX2-2 and MNX1 mutations as causes of neonatal diabetes in man. Cell Metab. 2014;19(1):146–154. doi:10.1016/j.cmet.2013.11.021
   Web of Science ®Google Scholar
• Smith SB, Qu H-Q, Taleb N, et al. Rfx6 directs islet formation and insulin production in mice and humans. Nature. 2010;463(7282):775–780. doi:10.1038/nature08748
   Web of Science ®Google Scholar
• Valenzuela I, Boronat S, Martínez-Sáez E, et al. Microcephaly with simplified gyral pattern, epilepsy and permanent neonatal diabetes syndrome (MEDS). A new patient and review of the literature. Eur J Med Genet. 2017;60(10):517–520. doi:10.1016/j.ejmg.2017.07.007
   Web of Science ®Google Scholar
• Bonnefond A, Vaillant E, Philippe J, et al. Transcription factor gene MNX1 is a novel cause of permanent neonatal diabetes in a consanguineous family. Diabetes Metab. 2013;39(3):276–280. doi:10.1016/j.diabet.2013.02.007
   Web of Science ®Google Scholar
• Greeley SAW, Naylor RN, Philipson LH, Bell GI. Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment. Curr Diab Rep. 2011;11(6):519–532. doi:10.1007/s11892-011-0234-7
   PubMed Web of Science ®Google Scholar